Catalent Launches FastChain Service for Clinical Supply Management

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-07-06-2016
Volume 11
Issue 7

Catalent’s FastChain service is a continuous GMP approach to clinical supply management that decouples primary packaging from secondary packaging, and enables the final assembly, labeling, and distribution of clinical supplies on a regional basis.

CDMO Catalent Pharma Solutions announced on June 27, 2016 the launch of its FastChain service, which the company says enables greater speed, flexibility, and efficiency in the management of global clinical supplies.

According to Catalent, this FastChain service is a continuous GMP approach to clinical supply management that decouples primary packaging from secondary packaging, and enables the final assembly, labeling, and distribution of clinical supplies on a regional basis.

This demand-led supply model reduces the need to pre-package bulk supplies far in advance of the study start, creates the ability to pool supplies across protocols, and has the potential to reduce clinical waste from upwards of 200% or more to less than 20%.

Investigator sites will receive only the clinical supplies they need to meet actual patient demand within a matter of days rather than weeks. Furthermore, mid-study changes such as revised dosing schedules or the addition of countries and clinical sites will be easy to accommodate for FastChain customers.

Catalents says it is making significant investments in its facilities worldwide to include specialized packaging lanes, and integrated systems and processes to support demand-led studies. The FastChain service will be made available for both ambient and cold chain studies on a global basis.

Source: Catalent

Recent Videos
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content